HOME > Business Wire > Article


Logo
Nov. 7, 2019 14:04 UTC

South Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance R&D Across Two Separate Programs for Oncology

TORONTO & SEOUL, South Korea--(BUSINESS WIRE)-- Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to apply Cyclicas proprietary AI-integrated drug discovery platform in two separate R&D programs. Yuhan is keen on implementing innovative technologies to enhance drug development efforts and will utilize Cyclicas unique end-to-end AI-integrated drug discovery platform across diverse therapeutic areas to develop novel advanced lead-like molecules with desired chemical properties against the targets of interest determined by Yuhans R&D priorities.

Yuhan will leverage Cyclicas integrated drug discovery platform, Ligand DesignTM and Ligand Express to generate novel chemical entities with desired polypharmacological, physicochemical, and ADMET properties while providing insights into systems biology and structural pharmacogenomics.

Cyclica will receive an upfront payment as well as receive milestone payments upon the completion of specific objectives. Through this collaboration, Yuhan and Cyclica envision a long-term relationship to enhance future R&D and drug discovery efforts to identify novel solutions for unaddressed therapeutic needs.

Yuhan CEO and President Jung Hee Lee said, We are very pleased to be collaborating with Cyclica to apply its proprietary AI-integrated drug discovery platform in our R&D programs, and hope to expand our partnership upon the success of the collaboration. Yuhan is dedicated to offering first-in-class to the patients within a short time by applying new computational methods, including AI and Big Data that can shorten the time and the cost required for drug development.

Its an honour to collaborate with Yuhan, a visionary company that is thinking deeply about the future of the discovery of better medicines, and the application of new computational methods, including machine and deep learning. I am confident that this collaboration, and the future relationship with Yuhan and Cyclica will benefit patients waiting for new and better medicines. said Naheed Kurji, President and CEO of Cyclica.

About Yuhan Corporation.

Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with the Clorox Company(USA) and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange.

About Cyclica Inc.

Cyclica is a Toronto-based, globally recognized biotechnology company that leverages AI and computational biophysics to reshape drug discovery. Cyclica provides the pharmaceutical industry with an integrated and end-to-end enabling drug discovery platform focused on polypharmacology. Ligand Design and Ligand Express offer a unique AI-augmented platform to design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. By doing more with artificial intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.

Contacts


Source: Cyclica

View this news release online at:
http://www.businesswire.com/news/home/20191107005619/en


The content of this press release is provided by Business Wire. If you
have any questions regarding the content, please contact the person(s)
identified in the CONTACTS box at the bottom of the release.

Business Wire


Aomori Tourism Information

HEADLINES

POLITICS
Govt to Review Abe-Hosted Cherry Blossom Party Procedure: Suga
ECONOMY
NY Stocks (Tuesday Closing): Dow 27,691.49 (Unchanged); Nasdaq 8,486.09 (+21.81)
SPORTS
Badminton Women: Fukushima-Hirota Pair Returns to Top of World Rankings
OTHER
Hayabusa2 to Leave Asteroid Ryugu for Earth on Wed.: JAXA

Aomori Tourism Information

GOSHOGAWARA
Introduction of Tachineputa, Town of Kanagi and West Tsugaru Peninsula
GOSHOGAWARA 1
GOSHOGAWARA 2
GOSHOGAWARA 3
JOMON
An early culture with pottery
JOMON 1
JOMON 2
JOMON 3
JOMON 4

AFP-JIJI PRESS NEWS JOURNAL


Photos